QA EngineerRobloxSan Mateo, CA, United States1 hour agoApplyEvery day, tens of millions of people come to Roblox to explore, create, play, learn, and connect with friends in 3D immersive digital experiences– all created by our global community of developers and creators.At Roblox, we’re building the tools and platform that empower our community to bring any experience that they can imagine to life. Our vision is to reimagine the way people come together, from anywhere in the world, and on any device. We’re on a mission to connect a billion people with optimism and civility, and looking for amazing talent to help us get there.A career at Roblox means you’ll be working to shape the future of human interaction, solving unique technical challenges at scale, and helping to create safer, more civil shared experiences for everyone.What You’ll Do:Help drive quality engineering efforts for internal and external product releasesHelp develop automated test strategies for existing and new, unreleased featuresDefine/implement/maintain test automation that drives improvements in Roblox usability, performance, hardware compatibility, and software interoperabilityDiagnose, debug, and perform root cause analysis for defects/incidents, document your findings, collaborate cross-functionally to triage, and champion resolution of your bugsCollaborate with Product Design, Program Management, Feature Developers, and other Quality Engineering team members to define requirements, ensure testability, and deliver high-quality featuresParticipate in the release process for RobloxCollaborate with partner teams to understand dependencies and to facilitate development of integration and end-to-end testsProvide technical support to internal team membersYou Are:Proficient in Python, JavaScript, and object-oriented programming using Kotlin, Swift, Objective-C, or similarExperienced with client and/or mobile test automation frameworksExperienced in defining/implementing/maintaining test coverage for a variety of platforms such as iOS, Android, Playstation, Quest VR, Google Chromebook, or similarProficient with version controland issue/project tracking softwareProficient with software development/debugging toolsExperienced with TestRail or similar test suite/case management toolsExperienced with Jenkins or similar build toolsHave a deep understanding of quality-related agile methodologies and experience applying them throughout the SDLCStrong communication skillsSkilled in analytical thinking, reporting, leadership, customer-centric approaches, and cross-functional collaborationFor roles that are based at our headquarters in San Mateo, CA: The starting base pay for this position is as shown below. The actual base pay is dependent upon a variety of job-related factors such as professional background, training, work experience, location, business needs and market demand. Therefore, in some circumstances, the actual salary could fall outside of this expected range. This pay range is subject to change and may be modified in the future. All full-time employees are also eligible for equity compensation and for benefits.Annual Salary Range— USDRoles that are based in our San Mateo, CA Headquarters are in-office Tuesday, Wednesday, and Thursday, with optional in-office on Monday and Friday.You’ll Love:Industry-leading compensation packageExcellent medical, dental, and vision coverageA rewarding 401k programFlexible vacation policyRoflex - Flexible and supportive work policyRoblox Admin badge for your avatarAt Roblox HQ:Free catered lunches five times a week and several fully stocked kitchens with unlimited snacksOnsite fitness center and fitness program creditAnnual CalTrain Go PassRoblox provides equal employment opportunities to all employees and applicants for employment and prohibits discrimination and harassment of any type without regard to race, color, religion, age, sex, national origin, disability status, genetics, protected veteran status, sexual orientation, gender identity or expression, or any other characteristic protected by federal, state or local laws. Roblox also provides reasonable accommodations for all candidates during the interview process. Create Your Profile — Game companies can contact you with their relevant job openings. Apply #engineer #roblox

The US Food and Drugs Administrationhas stated that it wants to accelerate the deployment of AI across its centres. FDA Commissioner Martin A. Makary has announced an aggressive timeline to scale use of AI by 30 June 2025 and is betting big on the technology to change drug approval processes for the US.But the rapid AI deployment at the FDA raises important questions about whether innovation can be balanced with oversight.Strategic leadership drive: FDA names first AI chiefThe foundation for the ambitious FDA AI deployment was laid with the appointment of Jeremy Walsh as the first-ever Chief AI Officer. Walsh previously led enterprise-scale technology deployments in federal health and intelligence agencies and came from government contractor Booz Allen Hamilton, where he worked for 14 years as chief technologist.His appointment, announced just before the May 8th rollout announcement, signals the agency’s serious commitment to technological transformation. The timing is significant – Walsh’s hiring coincided with workforce cuts at the FDA, including the loss of key tech talent.Among the losses was Sridhar Mantha, the former director of strategic programmes at the Center for Drug Evaluation and Research, who had co-chaired the AI Council at CDER and helped develop policy around AI’s use in drug development. Ironically, Mantha is now working alongside Walsh to coordinate the agency-wide rollout.The pilot programme: Impressive results, limited detailsWhat’s driving the rapid AI deployment is the reported success of the agency’s pilot programme trialling the software. Commissioner Makary said he was “blown away by the success of our first AI-assisted scientific review pilot,” with one official claiming the technology enabled him to perform scientific review tasks in minutes that used to take three days.However, the scope, rigour and results from the pilot scheme remain unreleased.The agency has not published detailed reports on the pilot’s methodology, validation procedures, or specific use cases tested. The lack of transparency is concerning given the high-stakes nature of drug evaluation.When pressed for details, the FDA has promised that additional details and updates on the initiative will be shared publicly in June. For an agency responsible for protecting public health through rigorous scientific review, the absence of published pilot data raises questions about the evidence base supporting such an aggressive timeline.Industry perspective: Cautious optimism meets concernsThe pharmaceutical industry’s reaction to the FDA AI deployment reflects a mixture of optimism and apprehension. Companies have long sought faster approval processes, with Makary pointedly asking, “Why does it take over 10 years for a new drug to come to market?”“While AI is still developing, harnessing it requires a thoughtful and risk-based approach with patients at the centre. We’re pleased to see the FDA taking concrete action to harness the potential of AI,” said PhRMA spokesperson Andrew Powaleny.However, industry experts are raising practical concerns. Mike Hinckle, an FDA compliance expert at K&L Gates, highlighted a key issue: pharmaceutical companies will want to know how the proprietary data they submit will be secured.The concern is particularly acute given reports that the FDA was in discussions with OpenAI about a project called cderGPT, which appears to be an AI tool for the Centre for Drug Evaluation and Research.Expert warnings: The rush vs rigour debateLeading experts in the field are expressing concern about the pace of deployment. Eric Topol, founder of the Scripps Research Translational Institute, told Axios: “The idea is good, but the lack of details and the perceived ‘rush’ is concerning.”He identified critical gaps in transparency, including questions about which models are being used to train the AI, and what inputs are provided for specialised fine-tuning.Former FDA commissioner Robert Califf struck a balanced tone: “I have nothing but enthusiasm tempered by caution about the timeline.” His comment reflects the broader sentiment among experts who support AI integration but question whether the June 30th deadline allows sufficient time for proper validation and safeguards to be implemented.Rafael Rosengarten from the Alliance for AI in Healthcare supports automation but emphasises the need for governance, saying there is a need for policy guidance around what kind of data is used to train AI models and what kind of model performance is considered acceptable.Political context: Trump’s deregulatory AI visionThe FDA AI deployment must be understood in the broader context of the Trump administration’s approach to AI governance. Trump’s overhaul of federal AI policy – ditching Biden-era guardrails in favour of speed and international dominance in technology – has turned the government into a tech testing ground.The administration has explicitly prioritised innovation over precaution. Vice President JD Vance outlined four key AI policy priorities, including encouraging “pro-growth AI policies” instead of “excessive regulation of the AI sector,” and he has taken action to ensure the forthcoming White House AI Action Plan would “avoid an overly precautionary regulatory regime.”The philosophy is evident in how the FDA is approaching its AI deployment. With Elon Musk leading a charge under an “AI-first” flag, critics warn that rushed rollouts at agencies could compromise data security, automate important decisions, and put Americans at risk.Safeguards and governance: What’s missing?While the FDA has promised that its AI systems will maintain strict information security and act in compliance with FDA policy, specific details about safeguards remain sparse. The agency’s claims that AI is a tool to support, not replace, human expertise and can enhance regulatory rigour by helping predict toxicities and adverse events. This provides some reassurance but lacks specificity.The absence of published governance frameworks for what is an internal process contrasts sharply with the FDA’s guidance for industry.The agency has previously issued draft guidance to pharma companies, providing recommendations on the use of AI intended to support a regulatory decision about a drug or biological product’s safety, effectiveness, or quality. Its published draft guidance in that instance was based on feedback from over 800 external comments and its experience with more than 500 drug submissions involving AI components in their development since 2016.The broader AI landscape: Federal agencies as testing groundsThe FDA’s initiative is part of a larger federal AI adoption wave. The General Services Administration is piloting an AI chatbot to automate routine tasks, and the Social Security Administration plans to use AI software to transcribe applicant hearings.However, GSA officials noted its tool has been in development for 18 months – highlighting the contrast with the FDA’s accelerated timeline, which at the time of writing, is a matter of weeks.The rapid federal adoption reflects the Trump administration’s belief that America is well-positioned to maintain its global dominance in AI and that the Federal Government must capitalise on the advantages of American innovation. It also maintains the importance of strong protections for Americans’ privacy, civil rights, and civil liberties.Innovation at a crossroadsThe FDA’s ambitious timeline embodies the fundamental tension between technological promise and regulatory responsibility. While AI offers clear benefits in automating tedious tasks, the rush to implementation raises critical questions about transparency, accountability, and the erosion of scientific rigour.The June 30th deadline will test whether the agency can maintain the public trust that has long been its cornerstone. Success requires more than technological capability – it demands proof that oversight hasn’t been sacrificed for speed.The FDA AI deployment represents a defining moment for pharmaceutical regulation. The outcome will determine whether rapid AI adoption strengthens public health protection or serves as a cautionary tale about prioritising efficiency over safety in matters of life and death. The stakes couldn’t be higher.See also: AI vs COVID-19: Here are the AI tools and services fighting coronavirusWant to learn more about AI and big data from industry leaders? Check out AI & Big Data Expo taking place in Amsterdam, California, and London. The comprehensive event is co-located with other leading events including Intelligent Automation Conference, BlockX, Digital Transformation Week, and Cyber Security & Cloud Expo.Explore other upcoming enterprise technology events and webinars powered by TechForge here. #fda #deployment #innovation #oversight #drug

In an industry where typefaces are designed to be used by thousands, a radical new concept has emerged that turns conventional type distribution on its head. David Březina, managing director at Rosetta Type, has created a typographic experiment called Only Yours: a typeface system that generates unique variants available exclusively to individual customers. The premise is brilliantly simple yet revolutionary: nine new variants of the typeface are released every day. Once purchased, a variant is permanently removed from circulation, ensuring that no one else will ever own that specific design. "The idea for a typeface that would be different for each customer has been on my mind for a few years," explains David. "According to surveys, most designers do not know how to use OpenType features and hence letter alternates. I'd been working on a still-unreleased typeface called Sacco, and at some point, it was so easy to create more and more letter alternates that it seemed like a shame to keep them tucked away somewhere in the font where no one would look." This observation sparked a more profound question: what if instead of hiding alternates within a font's features, the alternates themselves became the foundation for entirely unique typeface variants? Inspired by Dylan The concept lay dormant, though, until a surprising moment of inspiration. "I sat on it for a few years," recalls David. "The project seemed intimidating in scope, and I didn't really see a good reason to do it. "Then I went to see Bob Dylan, who's known for constantly rewriting his songs, in concert. It occurred to me that having so many perceivably different variants would bring more authenticity to the users. They could each have a unique font, in the same way concert-goers can attend a unique performance." This parallel between the legendary musician's ever-evolving performances and the notion of typographic uniqueness crystallised the concept. What began as design work in December 2025 led to a soft launch at the Automatic Type Design conference in Nancy, France, in February 2025. Science behind the system Only Yours isn't merely a stylistic exercise; it's grounded in David's PhD research on letter similarity perception. "I studied how they are clearly different, yet, in a well-designed font, they also look visually coherent," he explains. Technical implementation is where things become fascinatingly complex. Rather than designing alternative letters, David took a more fundamental approach. "Similarity perception is explained in terms of distinctive visual features that are shared by some of the letters, but not necessarily all of them," he explains. "More shared features mean stronger perceived similarity between the letters. It occurred to me that I could hack into this system and design alternates, not for the letters as we're used to from contemporary fonts, but for the individual features." While keeping some aspects of the generation process proprietary, David confirms that this feature-based approach allows for remarkable diversity while maintaining design coherence. "Using a reverse-contrast design remotely related to Antique Olive also helped to incorporate some rectangular elements more easily. The coherence does not need to be perfect, after all. Some of my favourite variants come from unexpected violations of the overall coherence." Scarcity as a feature, not a bug In an era of unlimited digital reproduction, Only Yours deliberately introduces scarcity. With over a million variants, the decision to release just nine per day transforms typography selection into something akin to a daily treasure hunt. "We didn't want to design a system for users to pick and choose," David notes. "The value of the project is not in providing all the options. It is in exclusivity. "Originally, I wanted the variant to be chosen randomly for the customers," he added. "But that did not seem right, so we settled on a compromise: offering nine new variants every day, which also turns it into a game. They're never shown again, so if you like one, you better get it." This approach creates a fascinating tension between the digital nature of typefaces and the artificial scarcity that makes each variant valuable. Once a customer purchases a weight from a variant, all weights within that variant become exclusive to them, preventing anyone else from fragmenting their unique typographic identity. Redefining typographic identity When sharing his concept with fellow designers before launch, David received some scepticism. "When I tried to discuss this idea with some friends, graphic designers, in November, they told me that it would be 'totally useless for branding'," he recalls with amusement. I disagree: since every variant is exclusive, it is perfect for branding!" Far from being an obstacle to professional use, the consistency within each variant across weights ensures practical usability while maintaining uniqueness. "Each variant of Only Yours is consistent across multiple weights, so it should work just fine in professional contexts," he asserts. The potential applications extend beyond individual designers. "Creating unique experiences in branding is not new. There is Freitag with their bags, each original, or even Coca-Cola with their named cans, which is a step in that direction," David points out. "Perhaps Only Yours could make it easier in some cases. We could, theoretically, generate thousands of unique variants for someone to licence as a bulk. Or a magazine could get a new variant for each issue." Looking to the future: Softly Yours Building on the success of Only Yours, Rosetta Type has already announced plans for Softly Yours, a rounded version using the same generative framework. "We set the price quite affordable to be more flexible," David adds. "We do have customers who already purchased multiple variants." Overall, this project represents a fascinating intersection of typographic design, computational creativity and exclusivity marketing. In a world increasingly concerned with digital ownership and authenticity, Rosetta Type has created something that feels almost paradoxical: a digital asset that can't be perfectly duplicated. For graphic designers and branding specialists, Rosetta Type offers something truly novel: the guarantee that your typographic voice won't be inadvertently duplicated by competitors. In an industry constantly searching for uniqueness, David has engineered it directly into the fabric of his typeface. As the nine variants change daily and customers claim their exclusive pieces of typographic history, Only Yours and Softly Yours aren't just new fonts. They represent a new relationship between designers and their tools, where scarcity, exclusivity and personal connection have been reintroduced to the digital realm. #only #yours #bold #new #approach

Tom's Hardware has acquired one of the first benchmarks for Phison's PS5028-E28 high-performance PCIe 5.0 SSD controller. Source: https://www.tomshardware.com/pc-components/ssds/exclusive-phison-e28-ssd-trashes-the-fastest-ssds-on-the-market-in-new-benchmark #exclusive #unreleased #phison #e28 #ssd #beats #the #fastest #ssds #market #new #benchmark